PTPL is an innovation driven company that integrates ‘omics’ approaches with artificial intelligence to develop novel platforms for disease prediction.
PredOmix is a technology development enterprise with an M&A as the exit point. Our present product represents a breakthrough platform that reliably identifies whether an individual will get type-2 diabetes within the next 3-5 years. It represents a novel technology with no competitor in the market so far. This platform is readily scalable and its scope will be expanded to cover other chronic diseases such as heart disease, and select cancers.